GlassScriptPhysician profile
Troy Alan Tyner
NPI 1003814526
$3,807.05
in general payments reported to CMS, 2019-2025
34 companies · $1,224 in 2025
The $1,224 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2020: $202 · 2021: $320 · 2022: $568 · 2023: $637 · 2024: $714 · 2025: $1,224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,574.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $385.05 | 2022-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $316.74 | 2021-2025 | Minimed 780g, Mycarelink, Azure Xt Dr Mri Surescan |
| Novo Nordisk INC | $304.02 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $296.84 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Abbott Laboratories | $281.09 | 2019-2025 | Freestyle Libre 3 |
| Abbvie INC. | $247.23 | 2021-2025 | Ubrelvy, Synthroid |
| Astrazeneca Pharmaceuticals LP | $228.99 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $210.81 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $189.09 | 2023-2025 | Evenity, Prolia, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $169.03 | 2022-2025 | |
| Corcept Therapeutics | $148.31 | 2020-2024 | Korlym |
| Medtronic Vascular, INC. | $107.98 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $104.35 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $86.45 | 2024-2025 | Zenpep |
| Xeris Pharmaceuticals, INC. | $75.46 | 2022-2025 | Gvoke Hypopen, Recorlev |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $74.55 | 2022-2023 | Verquvo, Steglatro, Belsomra |
| Amneal Pharmaceuticals LLC | $71.01 | 2023-2024 | Unithroid |
| Zealand Pharma US, INC. | $63.31 | 2020-2021 | |
| Tandem Diabetes Care, INC. | $56.39 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Exact Sciences Corporation | $54.68 | 2024 | Cologuard Collection Kit |
| Pfizer INC. | $50.33 | 2022-2023 | |
| Mannkind Corporation | $46.80 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $41.59 | 2022-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $35.44 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $34.72 | 2020-2021 | |
| Cequr Corporation | $30.67 | 2025 | Cequr Simplicity |
| Daiichi Sankyo INC. | $29.81 | 2022 | |
| Lifescan, INC. | $29.11 | 2020-2021 | |
| Esperion Therapeutics, INC. | $15.99 | 2021 | |
| Grt US Holding, INC. | $10.78 | 2022 | |
| Clarus Therapeutics INC. | $10.43 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troy Tyner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.